Drug lookup | Fillwise

BRIMONIDINE

All products: Limited Use (codes 171, 172, 387)

Other products in the same Health Canada class (S01E) — coverage varies; not interchangeable

Acetazolamide (Acetazolamide): general benefit, Not a benefit
Betaxolol (Betoptic S): general benefit
Levobunolol (Betagan): general benefit
Methazolamide (Neptazane): general benefit, Not a benefit
Timolol (Timoptic-XE): general benefit, Not a benefit
Bimatoprost (Lumigan): limited Use 171, 172, 387, Not a benefit

11 more in the class list below

Brimonidine P · DIN 02301334 · 0.15% · Oph Sol

Limited Use — Reason for Use code 171, 172, 387 requiredMarketed · checked 2026-09-19

StatusLimited Use — Reason for Use code 171, 172, 387 required

Write on scriptLU code 171, 172, 387 (patient must meet the criteria below)

Patient paysPatient pays: program not supplied; amount cannot be determined.

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ontario Limited Use criteria — code 171, 172, 387

Reason for Use code 171 As first line treatment of elevated intraocular pressure in patients who cannot tolerate an ophthalmic beta-blocking agent or where beta-blocking agents are contraindicated. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 172 As second line monotherapy or combination therapy in patients who do not have an adequate intraocular pressure lowering response to ophthalmic beta-blocking agents. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 387 For use as adjunctive therapy with an ophthalmic beta-blocking agent in an urgent situation (e.g. patients with a high baseline intraocular pressure) where monotherapy is unlikely to be effective. Coverage limit: LU Authorization Period: Indefinite

1 brand, same coverage

Brimonidine P · DIN 02301334 Manufacturer: A A Pharma Inc.; listing date 2008-10-01 Health Canada: Marketed since 2021-10-20 · brand BRIMONIDINE P · ATC S01EA05 BRIMONIDINE · form Solution · route Ophthalmic · ingredients BRIMONIDINE TARTRATE 0.15 %/W/V · company Aa pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Brimonidine P: Formulary list price $2.0305/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.0305 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666 · Verify on the e-Formulary ↗ (DIN 02301334)

Source record

DIN 02301334: Brimonidine P Raw flags: sec12=Y, sec3=Y Item: 523600107; group id 614; item number 1580; lccId 00082; manufacturer id AAP Source form: Oph Sol; strength: 0.15% Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $2.0305; ministry $2.0305 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02301334 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78666

Interchangeable products

Alphagan P · DIN 02248151 · $2.0305

Shortage status: not checked (no credentials)

Other drugs in the same formulary class (52:36 Other Eye, Ear, Nose and Throat Agents) and how they are covered

Matched class: 52:36 Other Eye, Ear, Nose and Throat Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BETAXOLOL HCL, DICLOFENAC SODIUM, LEVOBUNOLOL HCL Some products covered without a code (check the product listing): ACETAZOLAMIDE, METHAZOLAMIDE, SODIUM CROMOGLYCATE, TIMOLOL MALEATE 52:36 Other Eye, Ear, Nose and Throat Agents

ACETAZOLAMIDE

· 2 products · General benefit (1), Listed, not a benefit (1) · strengths: 250mg · Tab

BETAXOLOL HCL

· 1 products · General benefit · strengths: 0.25% · Oph Susp

LEVOBUNOLOL HCL

· 1 products · General benefit · strengths: 0.5% · Oph Sol

METHAZOLAMIDE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 50mg · Tab

TIMOLOL MALEATE

· 10 products · Listed, not a benefit (2), General benefit (8) · strengths: 0.25%, 0.5% · Oph Gellan Sol, Oph Sol

BIMATOPROST

· 8 products · Listed, not a benefit (1), Limited Use, codes 171, 172, 387 (7) · strengths: 0.03%, 0.01% · Oph Sol, Oph Sol-5mL Pk, Oph Sol-7.5mL Pk

BRIMONIDINE TARTRATE & TIMOLOL MALEATE

· 3 products · Limited Use, codes 310, 393 · strengths: 0.2% & 0.5% · Oph Sol-10mL Pk

BRINZOLAMIDE

· 1 products · Limited Use, codes 171, 172, 387 · strengths: 1% · Oph Susp

BRINZOLAMIDE & BRIMONIDINE TARTRATE

· 1 products · Limited Use, codes 466, 393 · strengths: 1.0% & 0.2% · Oph Susp-10mL Pk

BRINZOLAMIDE & TIMOLOL MALEATE

· 1 products · Limited Use, codes 310, 393 · strengths: 1% & 0.5% · Oph Susp-5mL Pk

DORZOLAMIDE HCL

· 5 products · Limited Use, codes 171, 172, 387 · strengths: 2% · Oph Sol

DORZOLAMIDE HCL & TIMOLOL MALEATE

· 11 products · Limited Use, codes 310, 393 · strengths: 2% & 0.5% · Oph Sol, Oph Sol-0.2mL Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 52:36 and 20 more

Full class listing Related classes: 52:04 Anti-Infectives, 52:08 Anti-Inflammatory Agents, 52:16 Local Anesthetics, 52:20 Miotics, 52:24 Mydriatics, 52:32 Vasoconstrictors Same formulary class, not same indication: class membership alone does not establish equivalent uses.

Other drugs whose Health Canada label lists a similar indication: the control of intraocular pressure

From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. BRIMONIDINE TARTRATE & TIMOLOL MALEATE · Limited Use, codes 310, 393 • the control of intraocular pressure (IOP) in patients with chronic open-angle glaucoma or ocular hypertension who are insufficiently responsive to IOP reducing monotherapy AND when the use of brimonidine tartrate 0.2%/timolol 0.5% (as timolol maleate) ophthalmic solution is considered appropriate. PM: https://pdf.hres.ca/dpd_pm/00070296.PDF; date December 14, 2022; DIN 02375311; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26

What the Health Canada label says it is for

1 INDICATIONS ALPHAGAN® (brimonidine tartrate) is indicated for:  the control of intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension 1.1 Pediatrics Pediatrics (< 18 years of age): The safety and efficacy of ALPHAGAN has not been established in pediatric patients; therefore, Health Canada has not authorized an indication for pediatric use. Several serious adverse reactions have been reported in association with the administration of brimonidine tartrate ophthalmic solution 0.2% in pediatric populations. See 2 CONTRAINDICATIONS, 7.1.3 Pediatrics and 8.2.1 Clinical Trial Adverse Reactions – Pediatrics. 1.2 Geriatrics Geriatrics (> 65 years of age): No overall difference in safety and effectiveness has been observed between elderly and other adult patients. https://pdf.hres.ca/dpd_pm/00067621.PDF PM date: NOV 24, 1997 Source product: ALPHAGAN; DIN 02236876; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.